Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis

Abstract Objectives The aim of this study was to assess the safety and efficacy of long-term low-dose glucocorticoids (GCs) in RA. Methods A protocolised systematic review and meta-analysis (PROSPERO No. CRD42021252528) of double-blind, placebo-controlled randomised trials (RCTs) comparing a low dos...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 62; no. 8; pp. 2652 - 2660
Main Authors Palmowski, Andriko, Nielsen, Sabrina M, Boyadzhieva, Zhivana, Schneider, Abelina, Pankow, Anne, Hartman, Linda, Da Silva, José A P, Kirwan, John, Wassenberg, Siegfried, Dejaco, Christian, Christensen, Robin, Boers, Maarten, Buttgereit, Frank
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.08.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Objectives The aim of this study was to assess the safety and efficacy of long-term low-dose glucocorticoids (GCs) in RA. Methods A protocolised systematic review and meta-analysis (PROSPERO No. CRD42021252528) of double-blind, placebo-controlled randomised trials (RCTs) comparing a low dose of GCs (≤ 7.5mg/day prednisone) to placebo over at least 2 years was performed. The primary outcome investigated was adverse events (AEs). We performed random-effects meta-analyses and used the Cochrane RoB tool and GRADE to assess risk of bias and quality of evidence (QoE). Results Six trials with 1078 participants were included. There was no evidence of an increased risk of AEs (incidence rate ratio 1.08; 95% CI 0.86, 1.34; P = 0.52); however, the QoE was low. The risks of death, serious AEs, withdrawals due to AEs, and AEs of special interest did not differ from placebo (very low to moderate QoE). Infections occurred more frequently with GCs (risk ratio 1.4; 1.19–1.65; moderate QoE). Concerning benefit, we found moderate to high quality evidence of improvement in disease activity (DAS28: −0.23; −0.43 to −0.03), function (HAQ −0.09; −0.18 to 0.00), and Larsen scores (–4.61; −7.52 to −1.69). In other efficacy outcomes, including Sharp van der Heijde scores, there was no evidence of benefits with GCs. Conclusion There is very low to moderate QoE for no harm with long-term low dose GCs in RA, except for an increased risk of infections in GC users. The benefit-risk ratio might be reasonable forusing low-dose long-term GCs considering the moderate to high quality evidence for disease-modifying properties.
AbstractList Abstract Objectives The aim of this study was to assess the safety and efficacy of long-term low-dose glucocorticoids (GCs) in RA. Methods A protocolised systematic review and meta-analysis (PROSPERO No. CRD42021252528) of double-blind, placebo-controlled randomised trials (RCTs) comparing a low dose of GCs (≤ 7.5mg/day prednisone) to placebo over at least 2 years was performed. The primary outcome investigated was adverse events (AEs). We performed random-effects meta-analyses and used the Cochrane RoB tool and GRADE to assess risk of bias and quality of evidence (QoE). Results Six trials with 1078 participants were included. There was no evidence of an increased risk of AEs (incidence rate ratio 1.08; 95% CI 0.86, 1.34; P = 0.52); however, the QoE was low. The risks of death, serious AEs, withdrawals due to AEs, and AEs of special interest did not differ from placebo (very low to moderate QoE). Infections occurred more frequently with GCs (risk ratio 1.4; 1.19–1.65; moderate QoE). Concerning benefit, we found moderate to high quality evidence of improvement in disease activity (DAS28: −0.23; −0.43 to −0.03), function (HAQ −0.09; −0.18 to 0.00), and Larsen scores (–4.61; −7.52 to −1.69). In other efficacy outcomes, including Sharp van der Heijde scores, there was no evidence of benefits with GCs. Conclusion There is very low to moderate QoE for no harm with long-term low dose GCs in RA, except for an increased risk of infections in GC users. The benefit-risk ratio might be reasonable forusing low-dose long-term GCs considering the moderate to high quality evidence for disease-modifying properties.
OBJECTIVESThe aim of this study was to assess the safety and efficacy of long-term low-dose glucocorticoids (GCs) in RA. METHODSA protocolised systematic review and meta-analysis (PROSPERO No. CRD42021252528) of double-blind, placebo-controlled randomised trials (RCTs) comparing a low dose of GCs (≤ 7.5mg/day prednisone) to placebo over at least 2 years was performed. The primary outcome investigated was adverse events (AEs). We performed random-effects meta-analyses and used the Cochrane RoB tool and GRADE to assess risk of bias and quality of evidence (QoE). RESULTSSix trials with 1078 participants were included. There was no evidence of an increased risk of AEs (incidence rate ratio 1.08; 95% CI 0.86, 1.34; P = 0.52); however, the QoE was low. The risks of death, serious AEs, withdrawals due to AEs, and AEs of special interest did not differ from placebo (very low to moderate QoE). Infections occurred more frequently with GCs (risk ratio 1.4; 1.19-1.65; moderate QoE). Concerning benefit, we found moderate to high quality evidence of improvement in disease activity (DAS28: -0.23; -0.43 to -0.03), function (HAQ -0.09; -0.18 to 0.00), and Larsen scores (-4.61; -7.52 to -1.69). In other efficacy outcomes, including Sharp van der Heijde scores, there was no evidence of benefits with GCs. CONCLUSIONThere is very low to moderate QoE for no harm with long-term low dose GCs in RA, except for an increased risk of infections in GC users. The benefit-risk ratio might be reasonable forusing low-dose long-term GCs considering the moderate to high quality evidence for disease-modifying properties.
The aim of this study was to assess the safety and efficacy of long-term low-dose glucocorticoids (GCs) in RA. A protocolised systematic review and meta-analysis (PROSPERO No. CRD42021252528) of double-blind, placebo-controlled randomised trials (RCTs) comparing a low dose of GCs (≤ 7.5mg/day prednisone) to placebo over at least 2 years was performed. The primary outcome investigated was adverse events (AEs). We performed random-effects meta-analyses and used the Cochrane RoB tool and GRADE to assess risk of bias and quality of evidence (QoE). Six trials with 1078 participants were included. There was no evidence of an increased risk of AEs (incidence rate ratio 1.08; 95% CI 0.86, 1.34; P = 0.52); however, the QoE was low. The risks of death, serious AEs, withdrawals due to AEs, and AEs of special interest did not differ from placebo (very low to moderate QoE). Infections occurred more frequently with GCs (risk ratio 1.4; 1.19-1.65; moderate QoE). Concerning benefit, we found moderate to high quality evidence of improvement in disease activity (DAS28: -0.23; -0.43 to -0.03), function (HAQ -0.09; -0.18 to 0.00), and Larsen scores (-4.61; -7.52 to -1.69). In other efficacy outcomes, including Sharp van der Heijde scores, there was no evidence of benefits with GCs. There is very low to moderate QoE for no harm with long-term low dose GCs in RA, except for an increased risk of infections in GC users. The benefit-risk ratio might be reasonable forusing low-dose long-term GCs considering the moderate to high quality evidence for disease-modifying properties.
Author Da Silva, José A P
Christensen, Robin
Palmowski, Andriko
Boers, Maarten
Wassenberg, Siegfried
Boyadzhieva, Zhivana
Nielsen, Sabrina M
Kirwan, John
Buttgereit, Frank
Schneider, Abelina
Pankow, Anne
Dejaco, Christian
Hartman, Linda
Author_xml – sequence: 1
  givenname: Andriko
  orcidid: 0000-0002-3456-0597
  surname: Palmowski
  fullname: Palmowski, Andriko
  email: andriko.palmowski@charite.de
– sequence: 2
  givenname: Sabrina M
  surname: Nielsen
  fullname: Nielsen, Sabrina M
– sequence: 3
  givenname: Zhivana
  surname: Boyadzhieva
  fullname: Boyadzhieva, Zhivana
– sequence: 4
  givenname: Abelina
  surname: Schneider
  fullname: Schneider, Abelina
– sequence: 5
  givenname: Anne
  surname: Pankow
  fullname: Pankow, Anne
– sequence: 6
  givenname: Linda
  surname: Hartman
  fullname: Hartman, Linda
– sequence: 7
  givenname: José A P
  orcidid: 0000-0002-2782-6780
  surname: Da Silva
  fullname: Da Silva, José A P
– sequence: 8
  givenname: John
  surname: Kirwan
  fullname: Kirwan, John
– sequence: 9
  givenname: Siegfried
  surname: Wassenberg
  fullname: Wassenberg, Siegfried
– sequence: 10
  givenname: Christian
  orcidid: 0000-0002-0173-0668
  surname: Dejaco
  fullname: Dejaco, Christian
– sequence: 11
  givenname: Robin
  surname: Christensen
  fullname: Christensen, Robin
– sequence: 12
  givenname: Maarten
  surname: Boers
  fullname: Boers, Maarten
– sequence: 13
  givenname: Frank
  orcidid: 0000-0003-2534-550X
  surname: Buttgereit
  fullname: Buttgereit, Frank
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36810945$$D View this record in MEDLINE/PubMed
BookMark eNqNkMtu3DAMRYUgQfPqHwSBlt24I0vyWOquCNIHEKCLZG9wJHpGiW1NRLkDf0D_O05nEnTZFUnw8l7inLPjIQ7I2FUpPpfCqkXa4NhDjl1cT4snBC-MOWJnpV7KQiglj997qU_ZOdGjEKIqlfnATtXSzB66OmN_7qHFPHEYPMe2DQ7cPBBFFyCj57uQN7yLw7rImPq52xU-EvJ1N7roYsrBxeCJh4G_PRQ8h5Q3KeRAXzhwmijjvAiOJ_wdcPc3rMcMBQzQTRTokp200BF-PNQL9vDt9uHmR3H36_vPm693hVO6zkW70vUKhbMajK9AKbVcOi0VtrWxyipXYbuSUoKxBoUordFCV2hqX8nKGXXBPu1ttyk-j0i56QM57DoYMI7UyLq2amZm7SzVe6lLkShh22xT6CFNTSmaV_7Nv_ybA__57PqQMK569O9Hb8BnwWIviOP2_yxfAOPam-8
CitedBy_id crossref_primary_10_1038_s41584_024_01120_w
crossref_primary_10_7326_M23_0192
crossref_primary_10_1055_a_2189_0667
crossref_primary_10_1093_rheumatology_kead309
crossref_primary_10_1001_jamanetworkopen_2024_14316
crossref_primary_10_1016_j_semarthrit_2023_152349
crossref_primary_10_1016_S2665_9913_23_00159_5
crossref_primary_10_1080_25785826_2023_2265148
crossref_primary_10_1093_rheumatology_keae077
crossref_primary_10_1093_rap_rkad102
crossref_primary_10_1093_rheumatology_kead167
crossref_primary_10_1016_j_addr_2024_115194
Cites_doi 10.1093/rheumatology/ket145
10.7326/0003-4819-146-6-200703200-00005
10.1136/annrheumdis-2020-219498
10.1002/acr.22860
10.1136/annrheumdis-2021-221957
10.1016/S0140-6736(14)61704-9
10.1002/acr.24596
10.1136/bmj.j4008
10.1002/acr2.11334
10.1136/annrheumdis-2013-204573
10.1136/ard.61.8.718
10.1016/j.jclinepi.2010.04.026
10.1093/rheumatology/key169
10.1186/s13063-017-2396-3
10.1136/annrheumdis-2016-210135
10.1136/ard.2003.014050
10.1093/rheumatology/kez087
10.1056/NEJM199507203330302
10.1037/1082-989X.8.3.243
10.1016/S0140-6736(08)61000-4
10.1002/art.21298
10.1371/journal.pone.0087965
10.1002/art.21519
10.1002/art.27592
10.1002/art.21421
10.1016/j.semarthrit.2020.02.016
10.1136/annrheumdis-2013-203440
10.1016/j.jclinepi.2013.03.009
10.1136/annrheumdis-2021-220134
10.1007/s00393-015-0019-5
10.1002/art.27268
10.1097/RHU.0000000000001749
10.1136/bmj.d5928
10.1016/j.semarthrit.2018.10.017
10.1136/annrheumdis-2019-216655
10.1136/annrheumdis-2016-210647
10.1093/cid/ciu185
10.1136/bmj.n71
10.1136/annrheumdis-2020-eular.689
10.1093/rheumatology/kep096
10.1093/rheumatology/15.1.17
10.1002/art.41754
ContentType Journal Article
Copyright The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2023
The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2023
– notice: The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
DBID NPM
AAYXX
CITATION
7X8
DOI 10.1093/rheumatology/kead088
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1462-0332
EndPage 2660
ExternalDocumentID 10_1093_rheumatology_kead088
36810945
10.1093/rheumatology/kead088
Genre Journal Article
GrantInformation_xml – fundername: The Section for Biostatistics and Evidence-Based Research
– fundername: The Parker Institute
– fundername: The Oak Foundation
  grantid: OCAY-18-774-OFIL
– fundername: European Union's Horizon 2020 Framework Programme for Research and Innovation
  grantid: 634886
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
08P
0R~
18M
1TH
29P
2WC
354
3O-
4.4
48X
53G
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAGKA
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABQTQ
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFXAL
AFXEN
AGINJ
AGKEF
AGSYK
AGUTN
AHMBA
AHXPO
AIAGR
AIJHB
AJEEA
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APWMN
AQDSO
ATGXG
ATTQO
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBD
EBS
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
KAQDR
KBUDW
KC5
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MHKGH
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RHF
RIG
RNI
ROL
ROX
RUSNO
RW1
RXO
RZF
RZO
SV3
TCURE
TEORI
TJX
TMA
TR2
VVN
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZY1
~91
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c347t-fb47be0c94a8d5a33366c423ef789393c5efb222a898e001984045e87d525c83
ISSN 1462-0324
IngestDate Fri Oct 25 00:53:22 EDT 2024
Fri Aug 23 00:37:16 EDT 2024
Wed Oct 16 00:39:08 EDT 2024
Wed Aug 28 03:15:22 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords safety
meta-analysis
glucocorticoids
adverse events
systematic review
efficacy
RA
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c347t-fb47be0c94a8d5a33366c423ef789393c5efb222a898e001984045e87d525c83
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-0173-0668
0000-0002-3456-0597
0000-0002-2782-6780
0000-0003-2534-550X
PMID 36810945
PQID 2779346299
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_2779346299
crossref_primary_10_1093_rheumatology_kead088
pubmed_primary_36810945
oup_primary_10_1093_rheumatology_kead088
PublicationCentury 2000
PublicationDate 2023-Aug-01
2023-08-01
20230801
PublicationDateYYYYMMDD 2023-08-01
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-Aug-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Rheumatology (Oxford, England)
PublicationTitleAlternate Rheumatology (Oxford)
PublicationYear 2023
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Palmowski (2023080221035358300_kead088-B42) 2020; 50
Palmowski (2023080221035358300_kead088-B44) 2019; 48
Emery (2023080221035358300_kead088-B36) 2010; 62
Graudal (2023080221035358300_kead088-B38) 2010; 62
Kourbeti (2023080221035358300_kead088-B27) 2014; 58
Emery (2023080221035358300_kead088-B35) 2008; 372
Fraenkel (2023080221035358300_kead088-B10) 2021; 73
Smolen (2023080221035358300_kead088-B3) 2014; 73
Schäfer (2023080221035358300_kead088-B32) 2021
Higgins (2023080221035358300_kead088-B19) 2011; 343
Chamberlain (2023080221035358300_kead088-B23) 1976; 15
Breedveld (2023080221035358300_kead088-B34) 2006; 54
Albrecht (2023080221035358300_kead088-B9) 2016; 75
Svensson (2023080221035358300_kead088-B22) 2005; 52
Kirwan (2023080221035358300_kead088-B37) 2007; 2010
Hetland (2023080221035358300_kead088-B5) 2020; 79
Capell (2023080221035358300_kead088-B24) 2004; 63
Safy (2023080221035358300_kead088-B39) 2017; 76
Bechman (2023080221035358300_kead088-B28) 2021; 73
Bechman (2023080221035358300_kead088-B30) 2019; 58
Boers (2023080221035358300_kead088-B18) 1994; 41
Boers (2023080221035358300_kead088-B15) 2022; 81
Vashisht (2023080221035358300_kead088-B45) 2016; 68
Hartman (2023080221035358300_kead088-B43) 2018; 19
Andersen (2023080221035358300_kead088-B7) 2022; 4
(2023080221035358300_kead088-B12) 2021
Palmowski (2023080221035358300_kead088-B1) 2019; 58
da Costa (2023080221035358300_kead088-B20) 2013; 66
Buttgereit (2023080221035358300_kead088-B14) 2002; 61
Guyatt (2023080221035358300_kead088-B21) 2011; 64
Kirwan (2023080221035358300_kead088-B16) 1995; 333
Page (2023080221035358300_kead088-B13) 2021; 372
Strangfeld (2023080221035358300_kead088-B31) 2021; 80
Boers (2023080221035358300_kead088-B40) 2013; 52
Nam (2023080221035358300_kead088-B4) 2014; 73
Goekoop-Ruiterman (2023080221035358300_kead088-B6) 2007; 146
Shea (2023080221035358300_kead088-B41) 2017; 358
van Sijl (2023080221035358300_kead088-B33) 2014; 9
Singh (2023080221035358300_kead088-B26) 2015; 386
Alves (2023080221035358300_kead088-B29) 2022; 28
Wassenberg (2023080221035358300_kead088-B17) 2005; 52
Roubille (2023080221035358300_kead088-B8) 2017; 76
Ravindran (2023080221035358300_kead088-B25) 2009; 48
Smolen (2023080221035358300_kead088-B2) 2020; 79
Cohn (2023080221035358300_kead088-B11) 2003; 8
References_xml – volume: 2010
  start-page: CD006356
  year: 2007
  ident: 2023080221035358300_kead088-B37
  article-title: Effects of glucocorticoids on radiological progression in rheumatoid arthritis
  publication-title: Cochrane Database Syst Rev
  contributor:
    fullname: Kirwan
– volume: 52
  start-page: 1435
  year: 2013
  ident: 2023080221035358300_kead088-B40
  article-title: A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/ket145
  contributor:
    fullname: Boers
– volume: 146
  start-page: 406
  year: 2007
  ident: 2023080221035358300_kead088-B6
  article-title: Comparison of treatment strategies in early rheumatoid arthritis
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-146-6-200703200-00005
  contributor:
    fullname: Goekoop-Ruiterman
– volume: 80
  start-page: 930
  year: 2021
  ident: 2023080221035358300_kead088-B31
  article-title: Factors associated with COVID-19–related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2020-219498
  contributor:
    fullname: Strangfeld
– volume: 68
  start-page: 1478
  year: 2016
  ident: 2023080221035358300_kead088-B45
  article-title: Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials
  publication-title: Arthritis Care & Research
  doi: 10.1002/acr.22860
  contributor:
    fullname: Vashisht
– volume: 81
  start-page: 925
  year: 2022
  ident: 2023080221035358300_kead088-B15
  article-title: Low dose, add-on prednisolone in patients with rheumatoid arthritis patients aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2021-221957
  contributor:
    fullname: Boers
– volume: 386
  start-page: 258
  year: 2015
  ident: 2023080221035358300_kead088-B26
  article-title: Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(14)61704-9
  contributor:
    fullname: Singh
– volume: 73
  start-page: 924
  year: 2021
  ident: 2023080221035358300_kead088-B10
  article-title: 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis
  publication-title: Arthritis Care Res
  doi: 10.1002/acr.24596
  contributor:
    fullname: Fraenkel
– volume: 358
  start-page: j4008
  year: 2017
  ident: 2023080221035358300_kead088-B41
  article-title: AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
  publication-title: BMJ
  doi: 10.1136/bmj.j4008
  contributor:
    fullname: Shea
– volume: 4
  start-page: 57
  year: 2022
  ident: 2023080221035358300_kead088-B7
  article-title: A bridge too far? Real-world practice patterns of early glucocorticoid use in the Canadian early arthritis cohort
  publication-title: ACR Open Rheumatol
  doi: 10.1002/acr2.11334
  contributor:
    fullname: Andersen
– volume: 73
  start-page: 492
  year: 2014
  ident: 2023080221035358300_kead088-B3
  article-title: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2013-204573
  contributor:
    fullname: Smolen
– volume: 61
  start-page: 718
  year: 2002
  ident: 2023080221035358300_kead088-B14
  article-title: Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.61.8.718
  contributor:
    fullname: Buttgereit
– volume: 64
  start-page: 383
  year: 2011
  ident: 2023080221035358300_kead088-B21
  article-title: GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2010.04.026
  contributor:
    fullname: Guyatt
– volume: 58
  start-page: 580
  year: 2019
  ident: 2023080221035358300_kead088-B1
  article-title: The 70th anniversary of glucocorticoids in rheumatic diseases: the second youth of an old friend
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/key169
  contributor:
    fullname: Palmowski
– volume: 19
  start-page: 67
  year: 2018
  ident: 2023080221035358300_kead088-B43
  article-title: Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial
  publication-title: Trials
  doi: 10.1186/s13063-017-2396-3
  contributor:
    fullname: Hartman
– volume: 76
  start-page: 1797
  year: 2017
  ident: 2023080221035358300_kead088-B8
  article-title: Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2016-210135
  contributor:
    fullname: Roubille
– volume: 63
  start-page: 797
  year: 2004
  ident: 2023080221035358300_kead088-B24
  article-title: Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2003.014050
  contributor:
    fullname: Capell
– volume: 58
  start-page: 1755
  year: 2019
  ident: 2023080221035358300_kead088-B30
  article-title: A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kez087
  contributor:
    fullname: Bechman
– volume: 333
  start-page: 142
  year: 1995
  ident: 2023080221035358300_kead088-B16
  article-title: The effect of glucocorticoids on joint destruction in rheumatoid arthritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199507203330302
  contributor:
    fullname: Kirwan
– volume: 8
  start-page: 243
  year: 2003
  ident: 2023080221035358300_kead088-B11
  article-title: How meta-analysis increases statistical power
  publication-title: Psychol Methods
  doi: 10.1037/1082-989X.8.3.243
  contributor:
    fullname: Cohn
– volume: 372
  start-page: 375
  year: 2008
  ident: 2023080221035358300_kead088-B35
  article-title: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(08)61000-4
  contributor:
    fullname: Emery
– volume: 52
  start-page: 3360
  year: 2005
  ident: 2023080221035358300_kead088-B22
  article-title: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21298
  contributor:
    fullname: Svensson
– volume: 9
  start-page: e87965
  year: 2014
  ident: 2023080221035358300_kead088-B33
  article-title: Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0087965
  contributor:
    fullname: van Sijl
– volume: 54
  start-page: 26
  year: 2006
  ident: 2023080221035358300_kead088-B34
  article-title: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21519
  contributor:
    fullname: Breedveld
– volume: 62
  start-page: 2852
  year: 2010
  ident: 2023080221035358300_kead088-B38
  article-title: Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons
  publication-title: Arthritis Rheum
  doi: 10.1002/art.27592
  contributor:
    fullname: Graudal
– volume: 52
  start-page: 3371
  year: 2005
  ident: 2023080221035358300_kead088-B17
  article-title: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21421
  contributor:
    fullname: Wassenberg
– volume: 50
  start-page: 1400
  year: 2020
  ident: 2023080221035358300_kead088-B42
  article-title: Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: a systematic review and meta-analysis
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2020.02.016
  contributor:
    fullname: Palmowski
– volume: 41
  start-page: 86
  year: 1994
  ident: 2023080221035358300_kead088-B18
  article-title: World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials
  publication-title: J Rheumatol Suppl
  contributor:
    fullname: Boers
– volume: 73
  start-page: 75
  year: 2014
  ident: 2023080221035358300_kead088-B4
  article-title: Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2013-203440
  contributor:
    fullname: Nam
– volume: 66
  start-page: 847
  year: 2013
  ident: 2023080221035358300_kead088-B20
  article-title: Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2013.03.009
  contributor:
    fullname: da Costa
– year: 2021
  ident: 2023080221035358300_kead088-B32
  article-title: Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Mulhearn et al
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2021-220134
  contributor:
    fullname: Schäfer
– volume: 75
  start-page: 90
  year: 2016
  ident: 2023080221035358300_kead088-B9
  article-title: [Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA]
  publication-title: Z Rheumatol
  doi: 10.1007/s00393-015-0019-5
  contributor:
    fullname: Albrecht
– volume: 62
  start-page: 674
  year: 2010
  ident: 2023080221035358300_kead088-B36
  article-title: Two-year clinical and radiographic results with combination etanercept–methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study
  publication-title: Arthritis Rheum
  doi: 10.1002/art.27268
  contributor:
    fullname: Emery
– volume: 28
  start-page: e407
  year: 2022
  ident: 2023080221035358300_kead088-B29
  article-title: The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis
  publication-title: J Clin Rheumatol
  doi: 10.1097/RHU.0000000000001749
  contributor:
    fullname: Alves
– volume: 343
  start-page: d5928
  year: 2011
  ident: 2023080221035358300_kead088-B19
  article-title: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
  publication-title: BMJ
  doi: 10.1136/bmj.d5928
  contributor:
    fullname: Higgins
– volume: 48
  start-page: 983
  year: 2019
  ident: 2023080221035358300_kead088-B44
  article-title: Applicability of trials in rheumatoid arthritis and osteoarthritis: a systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2018.10.017
  contributor:
    fullname: Palmowski
– volume: 79
  start-page: 685
  year: 2020
  ident: 2023080221035358300_kead088-B2
  article-title: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2019-216655
  contributor:
    fullname: Smolen
– volume: 76
  start-page: 1432
  year: 2017
  ident: 2023080221035358300_kead088-B39
  article-title: Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2016-210647
  contributor:
    fullname: Safy
– volume-title: Higgins JPT, Thomas J, Chandler J et al. (eds). Cochrane handbook for systematic reviews of interventions version 6.2
  year: 2021
  ident: 2023080221035358300_kead088-B12
– volume: 58
  start-page: 1649
  year: 2014
  ident: 2023080221035358300_kead088-B27
  article-title: Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciu185
  contributor:
    fullname: Kourbeti
– volume: 372
  start-page: n71
  year: 2021
  ident: 2023080221035358300_kead088-B13
  article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
  publication-title: BMJ
  doi: 10.1136/bmj.n71
  contributor:
    fullname: Page
– volume: 79
  start-page: 13
  year: 2020
  ident: 2023080221035358300_kead088-B5
  article-title: OP0018 A multicenter randomized study in early rheumatoid arthritis to compare active conventional therapy versus three biological treatments: 24 week efficacy results of the NORD-STAR trial
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2020-eular.689
  contributor:
    fullname: Hetland
– volume: 48
  start-page: 807
  year: 2009
  ident: 2023080221035358300_kead088-B25
  article-title: Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/kep096
  contributor:
    fullname: Ravindran
– volume: 15
  start-page: 17
  year: 1976
  ident: 2023080221035358300_kead088-B23
  article-title: The effect of low doses of prednisolone compared with placebo on function and on the hypothalamic pituitary adrenal axis in patients with rheumatoid arthritis
  publication-title: Rheumatol Rehabil
  doi: 10.1093/rheumatology/15.1.17
  contributor:
    fullname: Chamberlain
– volume: 73
  start-page: 1800
  year: 2021
  ident: 2023080221035358300_kead088-B28
  article-title: Nonserious infections in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.41754
  contributor:
    fullname: Bechman
SSID ssj0005138
Score 2.5299945
Snippet Abstract Objectives The aim of this study was to assess the safety and efficacy of long-term low-dose glucocorticoids (GCs) in RA. Methods A protocolised...
The aim of this study was to assess the safety and efficacy of long-term low-dose glucocorticoids (GCs) in RA. A protocolised systematic review and...
OBJECTIVESThe aim of this study was to assess the safety and efficacy of long-term low-dose glucocorticoids (GCs) in RA. METHODSA protocolised systematic...
SourceID proquest
crossref
pubmed
oup
SourceType Aggregation Database
Index Database
Publisher
StartPage 2652
Title Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/36810945
https://search.proquest.com/docview/2779346299
Volume 62
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIlW9IN5sechIHLiY7sZO4nADBFRI5UAXacUlchK7iUqTatltoXd-EX-QmdhJvFuQCpcoL9lS5os9Y3_zDSHPWonywOTMTDPOxLQQTBosGZaHSqgYIoQAs5EPPkb7n8WHeTgfjX55rKXVMnuRX_wxr-R_rAr3wK6YJfsPlu0bhRtwDvaFI1gYjley8aEyyLjEtW-NUhBYul25793Ryr829RHD8RfOzlmB9PSWpg5RJ7TXVJYQuyj1CnxXuETVo7JVOrJ50JtSz5ZBfKKXiiknaOI7uJ9cQ62yE0qZfu_Y865ciLf0gLVbmnNXOBuZldVxM-yT4KRtF2dVtqhqNazbvm5-qOKirPRZ6_l-KXE3q59eDvOyRvEuW6U7w3x75a9tBLxn1sHUZMdjEQVswvnagB0FHjClP_pGVg330rRgJbMW3heAy2P4iSa2pqCHldOTFiwcddoSq3S5IcjdPbpGrgcwuiGP8P3c4xVNuexyNBO-53e657rcIdtdI2vu0FqK5aVIp_V4ZjfJDReq0FcWd7fISNe3yfaBI2PcIT8t_CgYlXbwowP8KMKP9vCjHfzoBvxoVdMBfrSH30uq6AA-asHXdrYGvrtk9u7t7M0-c1U9WM5FvGQmE3GmJ3kilCxCxTmPohycem1i8J0TnofaZOC1KplIjRGIFBB2aBkXYRDmkt8jW3VT6weEFgLicSONiJRCjSM1NTKCV00USHRLx4R13zY9tdotqeVc8NQ3S-rMMibPwQBXfPVpZ6UUxmPcZFO1blbf0iAGTABqk2RM7lvz9S12Rt_965OHZGf4Dx6RreVipR-D17vMnrQo-w0O57fH
link.rule.ids 315,783,787,27938,27939
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+efficacy+associated+with+long-term+low-dose+glucocorticoids+in+rheumatoid+arthritis%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Palmowski%2C+Andriko&rft.au=Nielsen%2C+Sabrina+M&rft.au=Boyadzhieva%2C+Zhivana&rft.au=Schneider%2C+Abelina&rft.date=2023-08-01&rft.eissn=1462-0332&rft.volume=62&rft.issue=8&rft.spage=2652&rft_id=info:doi/10.1093%2Frheumatology%2Fkead088&rft_id=info%3Apmid%2F36810945&rft.externalDocID=36810945
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon